Core Viewpoint - Jiukang Bio has received a medical device registration certificate from the Beijing Drug Administration for its fibrinogen (pro) degradation product detection kit, indicating a significant regulatory milestone for the company [1] Group 1: Product Details - The product is a fibrinogen (pro) degradation product detection kit using the latex immunoturbidimetric method [1] - The registration certificate number is 京械注准20262400041, and it falls under Class II medical devices [1] - The certificate is valid until February 4, 2031, allowing for in vitro quantitative detection of fibrinogen (pro) degradation products in human plasma [1]

上述产品医疗器械注册证的取得，丰富了公司在体外诊断血凝细分领域 产品线的品种，有利于进一步提升公司的核心竞争力和市场拓展能力，对公 司未来的经营将产生积极影响。上述产品实际销售情况取决于未来市场推广 效果，公司目前尚无法预测其对公司未来业绩的影响，敬请投资者注意投资 风险。 特此公告。 北京九强生物技术股份有限公司 董事会 关于公司取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 纤维蛋白（原）降解 产物测定试剂盒（胶 乳免疫比浊法） | 京 械 注 准 20262400041 | Ⅱ | 自批准之日起有效期 至 2031 年 02 月 04 日 | 本试剂盒用于体外定量 检测人血浆中的纤维蛋 白（原）降解产物（FDP） 含量。 | | ...

Core Insights - The digital PCR (dPCR) technology is emerging as a significant advancement in nucleic acid detection, providing more precise and sensitive methods for quantitative analysis, addressing limitations of traditional PCR methods [1][10] - The Chinese digital PCR market is projected to grow from 1.584 billion yuan in 2019 to 8.815 billion yuan by 2025, with a compound annual growth rate (CAGR) of 33.1% [1][10] - The growth is driven by technological advantages and supportive national policies, with increasing recognition of its value among researchers and clinicians [1][10] Industry Overview - Digital PCR is categorized into droplet digital PCR (ddPCR) and chip digital PCR (cdPCR), allowing for absolute quantification without relying on standard curves, suitable for single-cell analysis and early cancer diagnosis [3][4] - The technology offers significant advantages over traditional PCR, including higher sensitivity, accuracy, and better tolerance to complex samples [4][5] Market Dynamics - The digital PCR industry is supported by a robust supply chain, with upstream components including essential biological materials and core parts like optical and fluid control components [6] - The midstream involves the research, production, and sales of digital PCR devices, with notable domestic companies like New Yi Biological and Zhenzhun Biological emerging as competitors [6][7] Application Areas - Digital PCR is utilized in various fields, including clinical diagnostics for pathogen detection, research for gene expression analysis, food safety testing, and agricultural applications [7][8] - In clinical settings, it plays a crucial role in early disease diagnosis and monitoring, particularly in oncology and infectious diseases [8] Competitive Landscape - The digital PCR market in China has seen the emergence of several domestic companies, with 16 manufacturers winning bids in 2024, of which 11 are local brands [12][12] - New Yi Biological and Linghang Gene lead in market share, with respective bid shares of 20% and 17.14% [12] Future Trends - Continuous technological innovation is expected to enhance detection efficiency and reduce costs, with advancements in multi-color fluorescence detection and microfluidic chip technology [16][17] - Collaboration among upstream suppliers, midstream manufacturers, and downstream application sectors will foster a synergistic development environment [17] - There is a growing focus on expanding into international markets, with domestic companies aiming to enhance their global presence and competitiveness [18][19]

Core Viewpoint - The company, Jiukang Biotechnology, has evolved from a代理商 to a leading player in the IVD (in vitro diagnostics) industry in China, focusing on innovation and precision diagnosis to drive future growth [2][3]. Group 1: Company Development - Jiukang Biotechnology started as an代理商 for an international IVD brand and quickly gained recognition, becoming a service supplier for the national quality control products [3]. - The company has maintained a strong client base, with over 70% of top-tier hospitals in China being loyal customers [3]. - The company has significantly increased its R&D investment, with R&D accounting for 21% of sales revenue in the first three quarters of 2025, up from 14% in the same period of 2024 [3]. Group 2: Product Innovation - R&D efforts are focused on new products in areas such as pathology, chemiluminescence, and coagulation, leading to an increase in medical device registrations and patents [4]. - The company has launched new products, including a high-speed fully automated chemiluminescence immunoassay analyzer and a biochemical analyzer, enhancing its competitive edge in the market [4]. - Jiukang's first AI project, a prostate cancer AI interpretation software, has been developed and validated, with plans to expand into smart pathology products [4]. Group 3: Strategic Partnerships - The company aims to become a platform enterprise in the IVD sector, collaborating with leading international firms to leverage their strengths and expand into global markets [5]. - A strategic partnership with Abbott began in 2013, allowing Jiukang to share its patented processes for global product production, resulting in profit-sharing [6]. - In 2020, a significant partnership with China National Pharmaceutical Group (Sinopharm) was established, enhancing sales channels and accelerating growth, with Sinopharm becoming the largest shareholder [6]. Group 4: Industry Trends - The IVD industry in China is rapidly developing, with significant growth potential driven by medical reform and innovation [7]. - The industry is expected to undergo a transformation towards high-quality upgrades, with a focus on value competition rather than price competition [7]. - Emerging technologies such as molecular diagnostics and AI-assisted diagnostics are anticipated to become core competitive advantages, with an emphasis on domestic alternatives in high-end markets [7].

截至2026年1月28日收盘，九强生物(300406)报收于13.89元，下跌2.87%，换手率2.43%，成交量10.31万 手，成交额1.44亿元。 当日关注点 交易信息汇总 资金流向 九强生物发布业绩预告，预计2025年全年扣非后净利润盈利1.71亿元至2.11亿元。九强生物发布业绩预 告，预计2025年全年归属净利润盈利1.8亿元至2.18亿元。 公司公告汇总 2025年度业绩预告 北京九强生物技术股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为18,000万 元至21,800万元，较上年同期下降66.21%至59.07%。扣除非经常性损益后的净利润预计为17,093万元至 21,093万元，同比下降67.16%至59.48%。业绩下降主要由于控股子公司美创公司受医疗行业政策影响， 拟计提商誉减值准备约1.8亿元，以及主营业务受政策影响导致盈利能力下滑。非经常性损益对净利润 的影响为707万元，主要为政府补助。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自【交易信息汇总】：1月28日主力资金净流 ...

Group 1 - The company expects a net profit attributable to shareholders of 180 million to 218 million yuan for 2025, representing a decline of 66.21% to 59.07% compared to the same period last year [1] - The net profit after deducting non-recurring gains and losses is projected to be between 170.93 million and 210.93 million yuan, reflecting a decrease of 67.16% to 59.48% year-on-year [1] - The company's subsidiary, Meichuang, is facing significant operational challenges due to the impact of medical industry policies, increased competition, and pressure on both volume and pricing [1] Group 2 - The company plans to recognize an impairment provision for goodwill of approximately 180 million yuan due to signs of impairment in related asset groups, following a cautious principle [1] - As of the date of this announcement, the goodwill impairment testing is still ongoing, and the final amount of the impairment provision will be determined based on evaluations and audits by qualified assessment and auditing institutions [1]

Group 1 - The company, Jiukang Bio, announced an expected net profit attributable to shareholders for the year 2025 to be between 180 million and 218 million yuan, representing a decline of 66.21% to 59.07% compared to the previous year's net profit of 532.6353 million yuan [1]

Core Viewpoint - Jiukang Bio (300406) has announced a significant decline in its expected net profit for 2025, projecting a decrease of 59.07% to 66.21% year-on-year [1] Financial Performance - The company expects the net profit attributable to shareholders to be between 180 million to 218 million yuan for 2025 [1] - The net profit after deducting non-recurring gains and losses is projected to be between 171 million to 211 million yuan, reflecting a year-on-year decline of 59.48% to 67.16% [1]

公告中解释本次业绩变动的原因为： 报告期内，公司所处体外诊断行业受政策影响，一方面增值税税率调整影响，另一方面业务受到医疗行 业政策影响，量价承压，公司盈利能力下滑，若不考虑商誉减值计提因素，经公司测算 2025 年度归属 于上市公司股东的净利润预计在 3.6 亿-3.98 亿之间，预计较上年同期下降 32%-25%。 1、资产减值计提 公司控股子公司美创公司受医疗行业政策影响，量价承压，行业竞争日益加剧，经营受到很大影响，出 于谨慎性原则，判断相关资产组商誉存在减值迹象，公司本期拟计提商誉减值准备约 1.8 亿元。截至本 公告披露日，相关商誉减值测试工作尚在进行中，最终商誉减值准备计提金额，将在公司聘请的具备证 券期货从业资格的评估机构及审计机构进行评估和审计的基础上，由公司履行内部的相关程序后确定。 2、主营业务影响 证券之星消息，九强生物发布业绩预告，预计2025年全年归属净利润盈利1.8亿元至2.18亿元。 公司结合自身状况和行业环境，积极发展病理产业，优化业务结构，发挥自身的技术优势，通过新产品 研发丰富自身的产品线，同时优化产品工艺，通过国产替代进口等降低成本，提升盈利能力。 3、2025 年，预 ...

智通财经APP讯，九强生物(300406.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 1.8亿元至2.18亿元，同比下降59.07%至66.21%;扣除非经常性损益后的净利润1.71亿元至2.11亿元，同比 下降59.48%至67.16%。 ...